Ori Zelichov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ori Zelichov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alice T. Shaw
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
1 shared publication - Gabi Tarcic
NovellusDx, Jerusalem Biopark, Hadassah Ein-Kerem Medical Center Campus, Jerusalem, Israel
1 shared publication - Jessica J. Lin
Department of Medicine, Mass General Brigham Cancer Institute, Boston, MA
1 shared publication - Justin I. Odegaard
Clinical Development, Guardant Health, 505 Penobscot Dr, Redwood City, CA, 94063 USA
1 shared publication - Lesli A. Kiedrowski
Guardant Health, Redwood City, California
1 shared publication - Rebecca J. Nagy
Guardant Health, Inc., 505 Penobscot Dr, Redwood City, CA 94063 USA
1 shared publication
Latest Publications
- Open Access
- 11 October 2019
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 8 (1) , 1-6
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib. We subsequently analyzed a large cohort of over 1800 additional patient samples harboring an EGFR T790M mutation and identified a concomitant L792 mutation in a total of 22 (1.2%) cases. In vitro functional assays demonstrated that the EGFR L858R/T790M/L792F/H mutations conferred intermediate-level resistance to osimertinib. Further understanding of potential acquired resistance mechanisms to targeted therapy may help inform treatment strategy in EGFR-mutant NSCLC.
- 11 October 2019
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 8 (1) , 1-6
Open AccessIdentification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib. We subsequently analyzed a large cohort of over 1800 additional patient samples harboring an EGFR T790M mutation and identified a concomitant L792 mutation in a total of 22 (1.2%) cases. In vitro functional assays demonstrated that the EGFR L858R/T790M/L792F/H mutations conferred intermediate-level resistance to osimertinib. Further understanding of potential acquired resistance mechanisms to targeted therapy may help inform treatment strategy in EGFR-mutant NSCLC.